A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 738 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Stage IV Cancer Patient Clinging to Life Overseas While Family Raises... May 28, 2020 FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers August 4, 2023 Listening to Patient Narratives June 9, 2020 Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of... February 2, 2022 Load more HOT NEWS HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... Intermittent Fasting ESMO Award for Immuno-Oncology 2025 Recipient Announced Health of Gut Microbes May Affect Survival after Stem Cell Transplant
